Geron Corp

Most Recent

• 

  .

  Company & Industry Overviews

  Geron: One of the Best-Performing Biotech Stocks in Past Month

  Geron (GERN) has been one of the best-performing biotechnology companies in the last month, rising 67.1% since August 10.

• 

  .

  Company & Industry Overviews

  Geron Stock Rose 32% in Week Ended August 24

  On August 24, Geron (GERN) stock rose ~28.78% to $5.19 from its prior day’s close of $4.03.

• 

  .

  Company & Industry Overviews

  Understanding Geron Corp’s IMerge Trial

  IMerge, a two-part clinical trial, is evaluating Geron’s (GERN) imetelstat in transfusion-dependent patients with low- or intermediate-risk myelodysplastic syndromes who have relapsed after or are refractory to prior treatment with an erythropoiesis-stimulating agent.

• 

  .

  Company & Industry Overviews

  A Look at Geron’s Imetelstat Research Program

  IMbark, a Phase 2 clinical trial, is evaluating two dose levels of Geron’s (GERN) imetelstat in ~200 myelofibrosis patients who have relapsed after or are refractory to prior treatment with a janus kinase inhibitor.

• 

  .

  Company & Industry Overviews

  A Close Look at Geron’s Imetelstat

  Geron contributes 50% of the development costs for the imetelstat trials. Imetelstat was granted fast track designation by the FDA in October 2017.

• 

  .

  Company & Industry Overviews

  XBI on a Downward Slope, but How Steep?

  On March 16, pressure on biotech and healthcare continued, with the SPDR S&P Biotech ETF (XBI) losing another 1.2% that day and closing at $48.31.

• 

  .

  Company & Industry Overviews

  Moving Averages of XBI’s Holdings Have Improved

  The moving averages of the stocks in the SPDR S&P Biotech ETF (XBI) have seen drastic improvements recently.

• 

  .

  Company & Industry Overviews

  How are IBB’s Subgroups Performing?

  The iShares Nasdaq Biotechnology ETF (IBB) gives good exposure to various industries in the biotechnology industry. As of October 19, IBB rose by ~0.5%.